Penn Medicine Provider
Gastroenterology
Gary R. Lichtenstein, MD
4.9
(413)
Accepting new patients
Sees patients age 18 and up
Penn Gastroenterology Perelman
Make an appointmentCall 215-349-8222

About me

  • Director, Inflammatory Bowel Disease Center
  • Professor of Medicine (Gastroenterology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: Mount Sinai School of Medicine
  • Residency: Duke University Medical Center
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating
4.9

413 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

July 2025
5.0
5.0
i am a long time pt of Dr Lichtenstein
June 2025
5.0
5.0
excellent dr
June 2025
5.0
5.0
great doctor
June 2025
5.0
5.0
he's gary lichtenstein

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Lichtenstein is a Penn Medicine physician.

Qualifications and experience

My research

Lichtenstein GR Exploring the Use of Terlipressin in Candidates for Liver Transplant. , Gastroenterol Hepatol (N Y) , 21(8): 2025,467

Farraye FA, Melmed GY, Lichtenstein GR, Barnes EL, Limketkai BN, Caldera F, Kane S ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease , American Journal of Gastroenterology, 120(7): 2025,1447-1473

Sehgal P, Lewis JD, Pickett-Blakely O, Nandi N, Bewtra M, Lichtenstein GR. Safety and Clinical Effectiveness of GLP1 Receptor Agonists in Inflammatory Bowel Disease Patients , Clinical Gastroenterology and Hepatology: 2025

Lichtenstein GR Exploring Irritable Bowel Syndrome Symptoms in Patients with Inflammatory Bowel Disease , Gastroenterol Hepatol (N Y) , 21(7): 2025,407

Lichtenstein GR Examining Exercise in Metabolic Dysfunction-Associated Steatohepatitis. , Gastroenterol Hepatol (N Y), 21(6): 2025,339

Lichtenstein GR, Loftus EV, Afzali A, Long MD, Barnes EL, Isaacs KL, Ha CY. ACG Clinical Guideline: Management of Crohn's Disease in Adults , American Journal of Gastroenterology, 120(6): 2025,1225-1264

Panaccione R, Vermeire S, Danese S, Higgins PDR, Lichtenstein GR, Nakase H, Glover S, Colombel JF, Eccleston J, Kujawski M, Remple V, Yao X, Geng Z, Palac H, Sharma D, Suravaram S, Schreiber S. Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study. , Lancet Gastroenterology Hepatology: 2025

Panaccione R, Lichtenstein GR, Colombel JF, Nakase H, Cheng E, Klaff J, et al. Efficacy and Safety of Upadacitinib After 4 Years of Treatment in Patients with Moderately to Severely Active Ulcerative Colitis: Interim Long-Term Data From the Phase 3 Open-Lable Extension Study (U-Activate). . , Gastroenterology : 2025

Khanna T, Sehgal P, Wang Y, Lichtentein GR. Real World Comparative Effectiveness of Upadacitinib Versus Tofacitinib in Ulcerative Colitis: A Propensity Matched Analysis. , Gastroenterology: 2025

Lichtenstein GR, Allegretti JR, Riubin DT, Feagan BG, Bressler B, Panés J, et al. Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study. , Gastroentrology: 2025

View all publications